Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 10,409 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Infection Viral Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

NCT00001031
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 60 Years
Enrollment
296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1997
U.S. locations
7
States / cities
Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

HIV and Fat Accumulation

NCT01088295
View directory record Official record
Conditions
HIV Infection
Interventions
Telmisartan
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Jul 23, 2026, 5:08 PM EDT
Terminated No phase listed Observational

Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma

NCT00767936
View directory record Official record
Conditions
Liver Cancer, Hepatitis B, Hepatitis C, Hepatobiliary Cancers Liver, Hepatobiliary Cancers
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Not applicable Interventional

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

NCT00002032
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Rifabutin
Drug
Lead sponsor
Pharmacia
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
33
States / cities
Irvine, California • Sylmar, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Phase 3 Interventional

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive

NCT00093093
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Viramidine, Ribavirin, pegylated interferon alfa-2a
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
53
States / cities
Tucson, Arizona • Fresno, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Not applicable Interventional

Qigong for Post Acute Sequelae of COVID-19 Infection

NCT05675995
View directory record Official record
Conditions
Long COVID
Interventions
Qigong
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C

NCT02118012
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Chlorcyclizine HCl, Ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Jul 23, 2026, 5:08 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

NCT07342881
View directory record Official record
Conditions
Chronic Hepatitis B Infection
Interventions
Pevifoscorvir Sodium (ALG-000184)
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Phase 1 Interventional

Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)

NCT04554992
View directory record Official record
Conditions
Covid19
Interventions
COVID 19 Convalescent Plasma
Biological
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Not applicable Interventional

A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

NCT00002432
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Evaluate a Human Monoclonal Antibody Against Hepatitis C

NCT00952263
View directory record Official record
Conditions
Healthy
Interventions
MBL-HCV1
Biological
Lead sponsor
MassBiologics
Other
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

NCT04191187
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Myeloproliferative Neoplasm, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed Marginal B-cell Lymphoma, Relapsed Follicular Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Fludarabine, Melphalan, Total Body Irradiation
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 23, 2026, 5:08 PM EDT
Completed No phase listed Observational Results available

COVID19 OutcomeS in Myeloma and the Impact of VaCcines

NCT05831787
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Patient Reported Outcomes
Other
Lead sponsor
ASH Research Collaborative
Other
Eligibility
Not listed
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Not applicable Interventional

OPTIONS: A Patient-Centered HIV Prevention Decision Aid for PrEP Uptake for Women With Substance Use in Treatment Settings

NCT03651453
View directory record Official record
Conditions
HIV Infections, Substance Abuse
Interventions
Decision aid, Standard care
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

NCT02040831
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV LID ΔM2-2 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children

NCT03387137
View directory record Official record
Conditions
RSV Infection
Interventions
RSV 6120/∆NS2/1030s, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 60 Months
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines

NCT00002402
View directory record Official record
Conditions
HIV Infections
Interventions
MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, MN rgp120/HIV-1 and A244 rgp120/HIV-1, Aluminum hydroxide
Biological
Lead sponsor
VaxGen
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
4
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 5:08 PM EDT
Recruiting Not applicable Interventional

The Effects of Chiropractic Care on Inflammation and Quality of Life in People Living With HIV

NCT07466836
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Chiropractic Care
Procedure
Lead sponsor
Tyson Perez, DC, PhD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines

NCT00076063
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV (vCP1452), LIPO-5
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
11
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Phase 2 Interventional

Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19

NCT06821087
View directory record Official record
Conditions
Long COVID
Interventions
Ketamine only
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older

NCT00979602
View directory record Official record
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
4,048 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
25
States / cities
Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

NCT02108639
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV 3DAA FDC, BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Phase 3 Interventional

A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

NCT00002377
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Valganciclovir, Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
15
States / cities
Irvine, California • La Jolla, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Jul 23, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

NCT02038881
View directory record Official record
Conditions
Smallpox
Interventions
IMVAMUNE®
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Jul 23, 2026, 5:08 PM EDT